| 840 |
Welcome & Opening Remarks |
Session 1: Movement disorders in the media
|
|
| 900 |
A journalist’s perspective on reporting medical advances |
| 920 |
Positive clinical trials in Huntington’s Disease |
| 940 |
Stem cell trials in Parkinson’s Disease |
| 1000 |
Media influence on the diagnosis of Tourette syndrome |
| 1020 |
Panel Discussion and Q&A |
| 10:40 |
BREAK |
Session 2: Improving movement disorders care |
|
| 1100 |
Standardizing MRI protocols for movement disorders |
| 1120 |
Evidence and best prescription for outpatient rehabilitation for movement disorders |
| 1140 |
Do the new DBS technologies improve movement disorders care? |
| 1200 |
Panel Discussion and Q&A |
| 12:20 |
LUNCH & Poster Session |
Access to movement disorders care in Canada – Part 1
|
|
| 1330 |
Debate #1: Access to genetic testing is necessary for current movement disorders care in Canada |
| 1415 |
Debate #2: Access to FDA-approved α-synuclein biomarkers is necessary for Parkinson’s disease care in Canada |
| 1500 |
Debate #3: Access to tertiary care centres is necessary for delivery of device-aided therapies for Parkinson’s disease (Tertiary care perspective/Community care perspective) |
| 15:45 |
BREAK |
Access to movement disorders care in Canada – Part 2
|
|
| 1600 |
Understanding Canada’s drug approval and reimbursement pathway |
| 1620 |
Drugs for movement disorders in Canada: what we don’t have and what we lost |
| 1640 |
Strategies to provide movement disorders care across the Canadian geography |
| 1700 |
Panel Discussion and Q&A |
| 1730 |
End of Day 1 |
| 1745 |
CMDS Annual General Meeting – CMDS Members Only |
| 1900 |
Food & Drinks – All Participants |
2026 Canadian Movement Disorders Society Congress
December 4 - 5, 2026
